Epidemiology, imaging, and treatment of giant cell arteritis.

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[2]  J. Hennig,et al.  Influence of corticosteroid treatment on MRI findings in giant cell arteritis , 2007, Clinical Rheumatology.

[3]  S. Berney,et al.  Treatment of refractory temporal arteritis with adalimumab , 2007, Clinical Rheumatology.

[4]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[5]  P. Lafforgue,et al.  Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. , 2007, Joint, bone, spine : revue du rhumatisme.

[6]  M. Langer,et al.  3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis , 2007, Clinical Rheumatology.

[7]  Scott D. Smith,et al.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. , 2006, Arthritis and rheumatism.

[8]  G. Hunder,et al.  Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. , 2006, Arthritis and rheumatism.

[9]  J. Hennig,et al.  High resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis , 2006, Journal of magnetic resonance imaging : JMRI.

[10]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[11]  J. Bratt,et al.  No additional steroid‐sparing effect of cyclosporine A in giant cell arteritis , 2006, Scandinavian journal of rheumatology.

[12]  M. Langer,et al.  Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. , 2005, Arthritis and rheumatism.

[13]  C. Butt,et al.  Etanercept in treatment of Felty’s syndrome , 2005, Annals of the rheumatic diseases.

[14]  E. Gromnica-ihle,et al.  What is the best approach to diagnosing large-vessel vasculitis? , 2005, Best practice & research. Clinical rheumatology.

[15]  M. González-Gay,et al.  Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. , 2005, The Journal of rheumatology.

[16]  John Ioannidis,et al.  Meta-Analysis: Test Performance of Ultrasonography for Giant-Cell Arteritis , 2005, Annals of Internal Medicine.

[17]  D. Schmidt,et al.  Color-coded sonography in suspected temporal arteritis—experiences after 83 cases , 2004, Rheumatology International.

[18]  M. Sonnenblick,et al.  Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. , 2004, Arthritis and rheumatism.

[19]  C. Nordborg,et al.  Giant cell arteritis: strategies in diagnosis and treatment , 2004, Current opinion in rheumatology.

[20]  E. Matteson,et al.  The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. , 2003, Clinical and experimental rheumatology.

[21]  K. Yasuda,et al.  Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. , 2003, Arthritis and rheumatism.

[22]  S. Hayreh,et al.  Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. , 2003, Ophthalmology.

[23]  C. Nordborg,et al.  The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. , 2003, Rheumatology.

[24]  M. Vinceti,et al.  Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis? , 2002, Annals of Internal Medicine.

[25]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[26]  L. Nyström,et al.  Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. , 2002, The Journal of rheumatology.

[27]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[28]  S. Feldon,et al.  The epidemiology of giant cell arteritis : a 12-year retrospective study. , 2001, Ophthalmology.

[29]  S. Larson,et al.  Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. , 2001, Archives of internal medicine.

[30]  M. González-Gay,et al.  Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period , 2001, Annals of the rheumatic diseases.

[31]  E. Hachulla,et al.  Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. , 2001, Clinical and experimental rheumatology.

[32]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[33]  G. Gran.  Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis - A prospective two-year study in 273 patients , 2001, Scandinavian journal of rheumatology.

[34]  G. Haugeberg,et al.  Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. , 2000, The Journal of rheumatology.

[35]  B. Grosbois,et al.  A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. , 2000, The Journal of rheumatology.

[36]  C. Nordborg,et al.  The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. , 1999, Rheumatology.

[37]  P. Roblot.  [Immunosuppressive agents in Horton's disease. Which drug for which indication?]. , 1998, Annales de medecine interne.

[38]  D. Ibañez,et al.  Long-term followup of patients receiving combined therapy with cyclosporine and methotrexate. , 1998, Arthritis and rheumatism.

[39]  E. Gromnica-ihle,et al.  Color duplex ultrasonography in the diagnosis of temporal arteritis. , 1997, The New England journal of medicine.

[40]  D. Ibañez,et al.  Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. , 1997, The Journal of rheumatology.

[41]  S. Gabriel,et al.  Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. , 1997, Arthritis and rheumatism.

[42]  G. A. van Albada-Kuipers,et al.  Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? , 1996, Annals of the rheumatic diseases.

[43]  G. Hunder,et al.  Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. , 1996, The American journal of medicine.

[44]  S. Gabriel,et al.  The Incidence of Giant Cell Arteritis in Olmsted County, Minnesota: Apparent Fluctuations in a Cyclic Pattern , 1995, Annals of Internal Medicine.

[45]  E. Gromnica-ihle,et al.  Colour doppler sonography to diagnose temporal arteritis , 1995, The Lancet.

[46]  M. Sonnenblick,et al.  Giant cell arteritis in Jerusalem: a 12-year epidemiological study. , 1994, British journal of rheumatology.

[47]  K. Chakravarty,et al.  A district audit on the management of polymyalgia rheumatica and giant cell arteritis. , 1994, British journal of rheumatology.

[48]  S. Bombardieri,et al.  Treatment of giant cell arteritis with cyclophosphamide pulses. , 1992, Journal of internal medicine.

[49]  J. Venot,et al.  Les décès dans la maladie de Horton, Facteurs de pronostic , 1992 .

[50]  C. Salvarani,et al.  Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. , 1991, Arthritis and rheumatism.

[51]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[52]  B. Bengtsson,et al.  Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. , 1989, BMJ.

[53]  A. Demaziere.  Dapsone in the long-term treatment of temporal arteritis. , 1989, The American journal of medicine.

[54]  G. Hunder,et al.  Polymyalgia rheumatica and giant-cell arteritis. , 1978, The New England journal of medicine.

[55]  M. González-Gay,et al.  Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. , 2004, Clinical and experimental rheumatology.

[56]  C. Dromer,et al.  [Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients]. , 1994, Revue du rhumatisme.

[57]  F. Boutros-Toni,et al.  [Clinical course of Horton disease. Apropos of 42 cured patients]. , 1994, Annales de medecine interne.